125 related articles for article (PubMed ID: 18069274)
21. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
Ludwig H; Spicka I; Klener P; Greil R; Adam Z; Gisslinger H; Tarkovács G; Linkesch W; Maniatis A; Morant R; Drach J; Kuhn I; Schuster J; Hinke A
Br J Haematol; 2005 Nov; 131(3):329-37. PubMed ID: 16225652
[TBL] [Abstract][Full Text] [Related]
22. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ
Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma.
Kasper B; Moehler T; Neben K; Ho AD; Goldschmidt H
Ann Oncol; 2004 Jan; 15(1):176-7. PubMed ID: 14679142
[No Abstract] [Full Text] [Related]
24. An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b.
Sirohi B; Powles R; Lawrence D; Treleaven J; Kulkarni S; Leary A; Rudin C; Horton C; Morgan G
Ann Oncol; 2007 Aug; 18(8):1388-94. PubMed ID: 17693652
[TBL] [Abstract][Full Text] [Related]
25. [Maintenance treatment of multiple myeloma-review].
Su JY; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):1111-7. PubMed ID: 19698272
[TBL] [Abstract][Full Text] [Related]
26. [Chemotherapy for multiple myeloma].
Ishida T
Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
[TBL] [Abstract][Full Text] [Related]
27. Low-dose thalidomide in myeloma: efficacy and biologic significance.
Durie BG
Semin Oncol; 2002 Dec; 29(6 Suppl 17):34-8. PubMed ID: 12520483
[TBL] [Abstract][Full Text] [Related]
28. New agents for the treatment of multiple myeloma and non-Hodgkin lymphoma.
Oken MM
Cancer; 1992 Aug; 70(4 Suppl):946-8. PubMed ID: 1638466
[TBL] [Abstract][Full Text] [Related]
29. [Study on the therapy of multiple myelomas--initial induction therapy (MP, IFN alpha, steroid pulse) and maintenance therapy (VMP, MP continuous, VEP, MCNU)].
Tanaka H; Kawano M; Iwato K; Asaoku H; Tanabe O; Ishikawa H; Nobuyoshi M; Sakai A; Kuramoto A
Rinsho Ketsueki; 1992 May; 33(5):655-61. PubMed ID: 1630017
[TBL] [Abstract][Full Text] [Related]
30. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Vangsted AJ; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Nexø BA; Vogel U
Ann Hematol; 2011 Oct; 90(10):1173-81. PubMed ID: 21347685
[TBL] [Abstract][Full Text] [Related]
31. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients.
Fritz E; Ludwig H
Ann Oncol; 2000 Nov; 11(11):1427-36. PubMed ID: 11142483
[TBL] [Abstract][Full Text] [Related]
32. Treatment options for relapsed and refractory multiple myeloma.
Lonial S; Mitsiades CS; Richardson PG
Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442
[TBL] [Abstract][Full Text] [Related]
33. Thalidomide in the treatment of multiple myeloma.
Kastritis E; Dimopoulos MA
Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
[TBL] [Abstract][Full Text] [Related]
34. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.
Mandelli F; Avvisati G; Amadori S; Boccadoro M; Gernone A; Lauta VM; Marmont F; Petrucci MT; Tribalto M; Vegna ML
N Engl J Med; 1990 May; 322(20):1430-4. PubMed ID: 2184356
[TBL] [Abstract][Full Text] [Related]
35. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
36. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
[TBL] [Abstract][Full Text] [Related]
37. Role of thalidomide in previously untreated patients with multiple myeloma.
Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
[TBL] [Abstract][Full Text] [Related]
38. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
[TBL] [Abstract][Full Text] [Related]
39. [Maintenance therapies of thalidomine and interferon-α in multiple myeloma].
Li J; Cai JH; Huang BH; Liu JR; Zheng D
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(48):3417-20. PubMed ID: 22333255
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]